Please assess the completion status of the following clinical trial:

Trial Title: Sentinel Lymph Node Biopsy in Breast Cancer Surgery Using ICG

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. the age of 18-75 years, female patients;~2. the diagnosis of breast cancer by biopsy;~3. participants voluntarily participated in the clinical trial and signed informed consent.~Exclusion Criteria:~1. had received SLNB or axillary surgery;~2. breast area radiotherapy or neoadjuvant chemotherapy has been accepted.~3. clinical hints of axillary lymph node metastasis;~4. discovery of distant metastasis;~5. inflammatory breast cancer;~6. women in pregnancy;~7. people with iodine allergy;~8. the serum creatinine was \> 1.5 times as high as the upper limit of the normal value.~9. to participate in clinical trials of other devices or drugs within one month;~10. the researchers consider it inappropriate to participate in this clinical trial.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Self control (Type: EXPERIMENTAL): During the operation, with the fluorescent molecular imaging instrument, the imaging agent (indocyanine green) is illuminated by the probe distance to the tissue surface 10-30cm, and is excited to produce the near infrared fluorescence of the specific wavelength (the human eye is not visible). The system uses a photoelectric coupler to collect the light of the specific spectrum, and the image is collected by the method of correction. The operation was performed to achieve real-time display of lesions.~The injection points were selected subcutaneously around the areola or the periphery of the tumor. 1% methylene blue 0.5ml was injected at each point, with a total of 2-3 points. Within 5 minutes, 2.5mg/ml ICG 0.5ml was injected at each point, with a total of 2-3 points.

Based on this trial design, predict the completion outcome and termination type (if applicable).